Cite

HARVARD Citation

    Matsuura, K. et al. (2022). A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC. Cancer. 128 (8), pp. 1692-1698. [Online]. 
  
Back to record